Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propofol WZF is an intravenous, short-acting anesthetic agent containing propofol, a substituted phenol derivative used for the induction and maintenance of general anesthesia. It primarily acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing inhibitory neurotransmission in the central nervous system. In the context of clinical research conducted by the Silesian University of Medicine, Propofol WZF was utilized for anesthesia induction in patients undergoing open renal surgery to evaluate the efficacy of thoracic paravertebral blocks in managing postoperative pain and reducing subsequent opioid requirements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Propofol WZF.